FORM 4

may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

X	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
---	--

1. Name and Address of Reporting Person* Rodman David Malcom			2. Issuer Name and Ticker or Trading Symbol <u>Mineralys Therapeutics, Inc.</u> [MLYS]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) (Middle) 150 N. RADNOR CHESTER ROAD,		()	3. Date of Earliest Transaction (Month/Day/Year) 04/14/2025	x	Director Officer (give title below) Chief Medica	10% Owner Other (specify below) 1 Officer		
SUITE F200			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person				
(Street) RADNOR	РА	19087		X	, ,	orting Person		
(City)	(State)	(Zip)						
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								

6. Ownership Form: Direct (D) 7. Nature of 1. Title of Security (Instr. 3) 2. Transaction 2A. Deemed 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Execution Date, Transaction Securities Indirect (Month/Dav/Year) if anv Code (Instr. **Beneficially Owned** or Indirect (I) Beneficial 8) (Month/Day/Year Following Reported (Instr. 4) Ownership Transaction(s) (Instr. 4) (A) or (D) (Instr. 3 and 4) Code v Amount Price 04/14/2025 **M**⁽¹⁾ 6,348 \$1.08 123,052 D Common Stock Α 04/14/2025 **S**⁽¹⁾ 2,966 D \$13.6929(2) 120,086 D Common Stock **S**⁽¹⁾ D D Common Stock 04/14/2025 8,400 \$14.83 111,686

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Option	\$1.08	04/14/2025		M ⁽¹⁾			6,348	(3)	07/11/2032	Common Stock	6,348	\$0	107,926	D	

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024.

2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$13.5382 to \$13.8250. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4

3. The stock option vested with respect to 25% of the underlying shares on July 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Remarks:

/s/ Adam Levy, Attorney-in-fact	04/15/2025
** Signature of Reporting Person	Date

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.